SNO 2022 - Society for Neuro-Oncology 27th Annual Scientific Meeting and Education Day
Nov 16 - Nov 20, 2022 | TampaFLUS
LARVOL is not affiliated with Society for Neuro-Oncology 27th Annual Scientific Meeting and Education Day and all trademarks, logos, and brand names are property of their respective owners
Showing 133 abstracts linked to Trials
Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial
Postprogression survival and MRI features at progression in MGMT-methylated glioblastoma following temozolomide (TMZ) or CCNU/TMZ therapy - an analysis of the CeTeG/NOA-09-trial
A phase I clinical trial on the intracranial administration of increasing doses of ipilimumab plus fixed dose nivolumab in patients with recurrent glioblastoma (rGB)
Phase II multicentric italian trial on repositioning of the antipsychotic drug chlorpromazine and its combination with temozolomide in MGMT unmethylated glioblastoma patients: the RACTAC trial
Genome-wide DNA methylation patterns in VERTU: A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with MGMT-unmethylated glioblastoma
Feasibility of a virtual reality (VR) intervention targeting distress and anxiety in primary brain tumor (PBT) patients at the time of neuroimaging: Interim analysis of a phase 2 clinical trial
Preclinical and case study examination of the combination of the CLPP agonist ONC201 with the PI3K/AKT inhibitor paxalisib for the treatment of diffuse midline glioma.
Quantification of glycolytic flux reduction in recurrent glioblastoma after EGFR inhibition using molecular MR-PET
Multilamellar mRNA lipid particles induce immunologic reprogramming in canine and human glioblastoma patients
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
CSNO2012001 study: A Phase III Trial on Adjuvant Temozolomide Chemotherapy with or without Interferon-alpha in Newly Diagnosed High-grade Gliomas
Preliminary results of binimetinib and encorafenib in adults with recurrent BRAF V600E-mutated high-grade glioma.
Clinical efficacy and predictive biomarkers of ONC201 in H3K27M-mutant diffuse midline glioma
Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors
Interim analysis of a phase II study of multiparametric MR-guided high-dose response-adaptive radiotherapy with concurrent temozolomide in patients with newly diagnosed glioblastoma